REG - Diaceutics PLC - Appointment of Amie Mc Neice as VP of Marketing

DiaceuticsAnnouncement

09/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240409:nRSI7585Ja&default-theme=true

RNS Number : 7585J  Diaceutics PLC  09 April 2024

Diaceutics appoints Amie Mc Neice as VP of Marketing

 

Belfast and London, 9 April 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce the appointment of Amie Mc Neice as Vice President of
Marketing. Amie previously held senior marketing and business development
roles with Almac Group, Fibrus and Kingspan Plc.

 

Amie brings a wealth of marketing leadership experience to the team and will
focus on delivering our 3-year marketing vision, brand positioning, messaging
and integration of marketing automation. Amie has significant experience in
working with US pharma customers.

 

Diaceutics is dedicated to scaling its sales and marketing capabilities in the
US and Europe through 2024.

 

Diaceutics continues to invest in product development with the further
expansion of its product management team in 2024. The product management team
will deliver our product roadmap and co-ordinate our product activities
across, data, scientific and medical services, engagement solutions,
engineering and marketing.

 

Jillian Beggs, Chief Commercial Officer of Diaceutics, commented: "I am
delighted to welcome Amie to the team at Diaceutics. Our continued investment
in sales and marketing supports our mission to provide the data, technology
solutions and insights that enable our pharma and biotech customers
revolutionise the commercialisation of their products and ultimately improve
patient outcomes."

 

Amie Mc Neice, VP Marketing of Diaceutics commented: "I have long admired
Diaceutics and look forward to working with the team as we expand our sales
and marketing capabilities and serve our customers' needs across the US and
Europe."

 

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison, Nick Harland, Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Kieran Breheny         diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKFBBFBKDPQK